Do you want to read an article? Please log in or register.
ESMO Basic Requirements for AI-based Biomarkers In Oncology (EBAI)
Further Publications
Indications
Related content
Breast Cancer
Breast cancer germline multigene panel testing in mainstream oncology based on clinical-public health utility: ESMO Precision Oncology Working Group recommendations
Ann Oncol
Turnbull C, Achatz MI, Balmaña J, Castro E, Curigliano G, Cybulski C, Domchek SM, Evans DG, Hanson H, Hoogerbrugge N, James PA, Krause A, Nathanson KL, Ngeow Yuen Yie J, Robson M, Tischkowitz M, Westphalen B, Foulkes WD
doi: 10.1016/j.annonc.2025.04.012
Genitourinary Cancer
Artificial Intelligence (AI)-based tools in the diagnosis and management of prostate cancer: a systematic review and meta-analysis
Prostate Cancer Prostatic Dis
Tun HM, Naing L, Malik OA, Rahman HA
doi: 10.1038/s41391-025-01060-w
Gynecologic Cancer
Oncological outcomes after radical hysterectomy followed by adjuvant (chemo)radiation or no further treatment in women with cervical cancer FIGO 2018 IB2-IIA2 - A multinational population-based cohort study
Eur J Cancer
Hardie AN, Wenzel HHB, Schnack TH, Van der Aa MA, Jensen PT, Bekkers RLM, Falconer H, Dutch, dANish and sweDish gynaEcoLogIcal ONcology (DANDELION) research group
doi: 10.1016/j.ejca.2025.115664
Lung, Respiratory and Thoracic Cancer
Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysis
Lancet Oncol
Di Federico A, Stumpo S, Mantuano F, De Giglio A, Lo Bianco F, Pecci F, Alessi JV, Wang X, Sperandi F, Melotti B, Gelsomino F, Skoulidis F, Garassino MC, Peters S, Awad MM, Ardizzoni A, Ricciuti B
doi: 10.1016/S1470-2045(25)00429-2
Breast Cancer
Endocrine-based strategies after CDK4/6 inhibitors in biomarker-selected subgroup of hormone receptor positive advanced breast cancer: A systematic review and network meta-analysis
Cancer Treat Rev
Escudero A, Bellet M, Saura C, Aguilera A, Papakonstantinou A, Tolosa P, García-Sáenz JÁ, Moreno F, López de Sá A, Schettini F, Seguí E, Gonzalez-Rodriguez M, Navarro V, Ferrero-Cafiero JM, González X, Hernando C, Matikas A, Prat A, Oliveira M, Pascual T, Villacampa G
doi: 10.1016/j.ctrv.2025.103063
Lung, Respiratory and Thoracic Cancer
Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: insights from the pembrolizumab 5-year global registry
J Immunother Cancer
Cortellini A, Santo V, Brunetti L, Garbo E, Pinato DJ, La Cava G, Naidoo J, Katz A, Loza M, Neal JW, Genova C, Gettinger S, Kim SY, Jayakrishnan R, El Zarif T, Russano M, Pecci F, Di Federico A, Alessi JV, Montrone M, Owen DH, Ramella S, Signorelli D, Fidler MJ, Li M, Camerini A, Halmos B, Vincenzi B, Metro G, Passiglia F, Yendamuri S, Guida A, Ghidini M, D'Alessio A, Banna GL, Fulgenzi CAM, Grisanti S, Grossi F, D'Incecco A, Josephides E, Van Hemelrijck M, Russo A, Gelibter A, Spinelli G, Verrico M, Tomasik B, Giusti R, Balachandran K, Bria E, Sebastian M, Rost M, Forster M, Mukherjee U, Landi L, Mazzoni F, Aujayeb A, Dupont M, Curioni-Fontecedro A, Chiari R, Sforza V, Tiseo M, Friedlaender A, Addeo A, Zoratto F, De Tursi M, Cantini L, Roca E, Mountzios G, Rocco D, Della Gravara L, Kalvapudi S, Inno A, Bironzo P, Di Marco Barros R, O'Reilly D, Fitzpatrick O, Karapanagiotou E, Monnet I, Baena J, Macerelli M, Piedra A, Agustoni F, Cortinovis DL, Tonini G, Minuti G, Bennati C, Mezquita L, Gorría T, Servetto A, Beninato T, Lo Russo G, Prelaj A, De Giglio A, Rogado J, Moliner L, Nadal E, Biello F, Nana FA, Dingemans AM, Aerts JGJV, Ferrara R, Abu Hejleh T, Takada K, Naqash AR, Garassino MC, Peters S, Wakelee HA, Nassar AH, Ricciuti B, Soda P, Caruso CM, Guarrasi V
doi: 10.1136/jitc-2025-012423
Lung, Respiratory and Thoracic Cancer
Chemoradiotherapy efficacy in patients with stage III non-small cell lung cancer (NSCLC): A prognostic clinical and biomarker-based model
Lung Cancer
Vaes RDW, Cortiula F, Lyu S, Hiltermann TJN, Houben R, Degens J, Hendriks LEL, Ruysscher D
doi: 10.1016/j.lungcan.2025.108541
Breast Cancer
Body mass index as a predictive factor for efficacy of adjuvant taxane-based chemotherapy in early-stage breast cancer patients: A pooled analysis from adjuvant GEICAM Spanish Breast Cancer Group and TRIO Translational Research in Oncology Group studies
Int J Cancer
García-Saenz JA, Spera G, Pollán M, Bermejo B, Ruiz-Borrego M, Chan A, Martín M, Guerrero-Zotano Á, Calvo L, Rodríguez-Lescure Á, Marín M, Chap L, Crown J, Pienkowski T, Bee V, Casas M, Polonio Ó, Bezares S, Slamon D
doi: 10.1002/ijc.35432
Skin Cancer
Clinical validation of droplet digital PCR assays in detecting BRAF(V600)-mutant circulating tumour DNA as a prognostic biomarker in patients with resected stage III melanoma receiving adjuvant therapy (COMBI-AD): a biomarker analysis from a double-blind, randomised phase 3 trial
Lancet Oncol
Syeda MM, Long GV, Garrett J, Atkinson V, Santinami M, Schadendorf D, Hauschild A, Millward M, Mandala M, Chiarion-Sileni V, Smylie M, Manikhas GM, Dummer R, Wiggins JM, Ali S, Adnaik SB, Tan M, Dajee M, Polsky D
doi: 10.1016/S1470-2045(25)00139-1